Company / Working Capital
RAPT Therapeutics, Inc. Working Capital History
FY2018-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Working Capital
$186.9M
FY2024
5-year range
$103.9M / $238.5M
FY2020-FY2024
Trend
+33.5%
vs FY2023
Sector context
#172 of 214
Health Care
What the data says
RAPT Therapeutics, Inc.'s working capital of $187M is lower than 80% of companies in the Health Care sector (FY2024). Declined from $238M to $187M over the past 2 years.
Based on SEC 10-K filings.
$187M in FY2024 with a 5-year CAGR of +21.3%.
Declined from $238M to $187M over the past 2 years.
Health Care sector context is included.
Working Capital over time
Growth rates
- 3-Year CAGR
- +0.6%
- 5-Year CAGR
- +21.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 214This company $186.9M Sector average $955.5M
▼
-80.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +21.3%, indicating consistent growth.
- In FY2024, working capital increased 33.5% year-over-year.
- Ranks #172 out of 214 companies in the Health Care sector.
- Peak working capital was recorded in FY2022.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score 0.38 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Working CapitalValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $186.9M | +33.5% |
| FY2023 | $139.9M | -41.3% |
| FY2022 | $238.5M | +30.0% |
| FY2021 | $183.4M | +76.6% |
| FY2020 | $103.9M | +45.8% |
| FY2019 | $71.3M | +17.9% |
| FY2018 | $60.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026